Pharma CI · The Public Record
Explore my Pharma CI work.
Competitive intelligence is my full-time profession — I'm a Director of Competitive Intelligence at a leading life sciences advisory firm. It is not a side practice, and this page is not a service offering. It's simply the public record of that work, collected in one place: the published analysis, the webinars and panels, and the peer-reviewed research.
2026 · Media intelligence
Fierce Biotech2026
“Money has spoken”: Why Chinese biotech CEOs tell Fierce they’re unfazed about rising US tensions
Featured biopharma expert →
BioSpace2026
No Longer a Bargain Pool, Chinese Biotechs Command Higher Premiums
Featured expert →
Citeline2026
Ask the Analyst — Expert Profile
Listed expert: health policy, market dynamics, forecasting & market access →
2024 · Analysis & appearances
Evaluate2024
Orphans are Getting Strategic
Author →
Evaluate2024
Orphan Drugs: Are They Losing Their Sparkle?
Panelist →
Evaluate2024
In Case You Missed It: Three Things We Learned in Our Orphan Drugs Webinar
Featured analyst / recap →
PharmaVoice2024
Pfizer’s Quest for Market Share in the “High Stakes Battleground” of Oral GLP-1s
Featured commercial expert →
GEN / GEN Edge2024
StockWatch: Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk
Featured analysis →
MM+M2024
Novo Nordisk’s GLP-1 Sales Surge, but Q2 Earnings Disappoint
Featured earnings analysis →
MM+M2024
Despite COVID-19 Product Dip, Pfizer Raises Full Year Outlook
Featured earnings commentary →
Investor’s Business Daily2024
Merck Stock Jumps As It Looks To Add A $1 Billion To $15 Billion Deal
Featured industry commentary →
In Vivo2024
Unraveling JPM24: Insights From Citeline Reporters And Analysts
Industry analysis →
In Vivo2024
What Big Pharmas Are Looking For In Partners
Business development →
Citeline2024
Unraveling #JPM24: The Impact for You and the Industry
Panelist →